|
1
|
Li L and Fu R: Advances in targeted drug
therapy for relapse/refractory diffuse large B-cell lymphoma. Chin
J Clin Oncol. 46:581–585. 2019.
|
|
2
|
Dunleavy K, Erdmann T and Lenz G:
Targeting the B-cell receptor pathway in diffuse large B-cell
lymphoma. Cancer Treat Rev. 65:41–46. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chiappella A, Santambrogio E, Castellino
A, Nicolosi M and Vitolo U: Integrating novel drugs to
chemoimmunotherapy in diffuse large B-cell lymphoma. Expert Rev
Hematol. 10:697–705. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu P and Zhao W: The interpretation of the
Chinese society of clinical oncology clinical guidelines for the
diagnosis and treatment of diffuse large B-cell lymphoma. West Chin
Med J. 34:351–354. 2019.
|
|
5
|
Vaqué JP, Martínez N, Batlle-López A,
Pérez C, Montes-Moreno S, Sánchez-Beato M and Piris MA: B-cell
lymphoma mutations: Improving diagnostics and enabling targeted
therapies. Haematologica. 99:222–231. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhu Z, Hou Q and Guo H: NT5DC2 knockdown
inhibits colorectal carcinoma progression by repressing metastasis,
angiogenesis and tumor-associated macrophage recruitment: A
mechanism involving VEGF signaling. Exp Cell Res. 397:1123112020.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jin X, Liu X, Zhang Z and Xu L: NT5DC2
suppression restrains progression towards metastasis of
non-small-cell lung cancer through regulation p53 signaling.
Biochem Biophys Res Commun. 533:354–361. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen J, Cao J, Wang P and He X: NT5DC2 is
a novel prognostic marker in human hepatocellular carcinoma. Oncol
Lett. 20:702020.PubMed/NCBI
|
|
9
|
Li KS, Zhu XD, Liu HD, Zhang SZ, Li XL,
Xiao N, Liu XF, Xu B, Lei M, Zhang YY, et al: NT5DC2 promotes tumor
cell proliferation by stabilizing EGFR in hepatocellular carcinoma.
Cell Death Dis. 11:3352020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guo S, Ran H, Xiao D, Huang H, Mi L, Wang
X, Chen L, Li D, Zhang S, Han Q, et al: NT5DC2 promotes
tumorigenicity of glioma stem-like cells by upregulating fyn.
Cancer Lett. 454:98–107. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bell JL, Wächter K, Mühleck B, Pazaitis N,
Köhn M, Lederer M and Hüttelmaier S: Insulin-like growth factor 2
mRNA-binding proteins (IGF2BPs): Post-transcriptional drivers of
cancer progression? Cell Mol Life Sci. 70:2657–2675. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nielsen J, Christiansen J, Lykke-Andersen
J, Johnsen AH, Wewer UM and Nielsen FC: A family of insulin-like
growth factor II mRNA-binding proteins represses translation in
late development. Mol Cell Biol. 19:1262–1270. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gong C, Li Z, Ramanujan K, Clay I, Zhang
Y, Lemire-Brachat S and Glass DJ: A long non-coding RNA, LncMyoD,
regulates skeletal muscle differentiation by blocking IMP2-mediated
mRNA translation. Dev Cell. 34:181–191. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li Z, Gilbert JA, Zhang Y, Zhang M, Qiu Q,
Ramanujan K, Shavlakadze T, Eash JK, Scaramozza A, Goddeeris MM, et
al: An HMGA2-IGF2BP2 axis regulates myoblast proliferation and
myogenesis. Dev Cell. 23:1176–1188. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Degrauwe N, Schlumpf TB, Janiszewska M,
Martin P, Cauderay A, Provero P, Riggi N, Suvà ML, Paro R and
Stamenkovic I: The RNA binding protein IMP2 preserves glioblastoma
stem cells by preventing let-7 target gene silencing. Cell Rep.
15:1634–1647. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Janiszewska M, Suvà ML, Riggi N,
Houtkooper RH, Auwerx J, Clément-Schatlo V, Radovanovic I, Rheinbay
E, Provero P and Stamenkovic I: Imp2 controls oxidative
phosphorylation and is crucial for preserving glioblastoma cancer
stem cells. Genes Dev. 26:1926–1944. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Simon Y, Kessler SM, Bohle RM, Haybaeck J
and Kiemer AK: The insulin-like growth factor 2 (IGF2) mRNA-binding
protein p62/IGF2BP2-2 as a promoter of NAFLD and HCC? Gut.
63:861–863. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pu J, Wang J, Qin Z, Wang A, Zhang Y, Wu
X, Wu Y, Li W, Xu Z, Lu Y, et al: IGF2BP2 promotes liver cancer
growth through an m6A-FEN1-dependent mechanism. Front Oncol.
10:5788162020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu X, Yu Y, Zong K, Lv P and Gu Y:
Up-regulation of IGF2BP2 by multiple mechanisms in pancreatic
cancer promotes cancer proliferation by activating the PI3K/Akt
signaling pathway. J Exp Clin Cancer Res. 38:4972019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lenz G and Staudt LM: Aggressive
lymphomas. N Engl J Med. 362:1417–1429. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Darbà J and Marsà A: Burden of Hodgkin and
non-Hodgkin lymphoma in Spain over a 10-year period: productivity
losses due to premature mortality. Expert Rev Pharmacoecon Outcomes
Res. 21:87–92. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shiozawa T, Tadokoro J, Fujiki T, Fujino
K, Kakihata K, Masatani S, Morita S, Gemma A and Boku N: Risk
factors for severe adverse effects and treatment-related deaths in
Japanese patients treated with irinotecan-based chemotherapy: A
postmarketing survey. Jpn J Clin Oncol. 43:483–491. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Barz MJ, Hof J, Groeneveld-Krentz S, Loh
JW, Szymansky A, Astrahantseff K, von Stackelberg A, Khiabanian H,
Ferrando AA, Eckert C and Kirschner-Schwabe R: Subclonal NT5C2
mutations are associated with poor outcomes after relapse of
pediatric acute lymphoblastic leukemia. Blood. 135:921–933. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dieck CL and Ferrando A: Genetics and
mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL.
Blood. 133:2263–2268. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hu B, Zhou S, Hu X, Zhang H, Lan X, Li M,
Wang Y and Hu Q: NT5DC2 promotes leiomyosarcoma tumour cell growth
via stabilizing unpalmitoylated TEAD4 and generating a positive
feedback loop. J Cell Mol Med. 25:5976–5987. 2021.(Epub ahead of
print). View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ogrodnik M, Salmonowicz H, Jurk D and
Passos JF: Expansion and cell-cycle arrest: Common denominators of
cellular senescence. Trends Biochem Sci. 44:996–1008. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Voss AK and Strasser A: The essentials of
developmental apoptosis. F1000Res. 9:F1000 Faculty Rev. –148. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Burgess DJ: Apoptosis: Refined and lethal.
Nat Rev Cancer. 13:792013. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hollstein M, Sidransky D, Vogelstein B and
Harris CC: p53 mutations in human cancers. Science. 253:49–53.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ventura A, Kirsch DG, McLaughlin ME,
Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R
and Jacks T: Restoration of p53 function leads to tumour regression
in vivo. Nature. 445:661–665. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Xue W, Zender L, Miething C, Dickins RA,
Hernando E, Krizhanovsky V, Cordon-Cardo C and Lowe SW: Senescence
and tumour clearance is triggered by p53 restoration in murine
liver carcinomas. Nature. 445:656–660. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tessoulin B, Eveillard M, Lok A, Chiron D,
Moreau P, Amiot M, Moreau-Aubry A, Le Gouill S and
Pellat-Deceunynck C: p53 dysregulation in B-cell malignancies: More
than a single gene in the pathway to hell. Blood Rev. 31:251–259.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lu TX, Young KH, Xu W and Li JY: TP53
dysfunction in diffuse large B-cell lymphoma. Crit Rev Oncol
Hematol. 97:47–55. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Drakos E, Singh RR, Rassidakis GZ,
Schlette E, Li J, Claret FX, Ford RJ Jr, Vega F and Medeiros LJ:
Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a
overcomes BCL2 overexpression in a preclinical model of diffuse
large B-cell lymphoma associated with t(14;18)(q32;q21). Leukemia.
25:856–867. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Luo Q, Pan W, Zhou S, Wang G, Yi H, Zhang
L, Yan X, Yuan L, Liu Z, Wang J, et al: A novel BCL-2 inhibitor
APG-2575 exerts synthetic lethality with BTK or MDM2-p53 inhibitor
in diffuse large B-cell lymphoma. Oncol Res. 28:331–344. 2020.
View Article : Google Scholar : PubMed/NCBI
|
